Good morning, everyone, and welcome to our 2025 year-end and fourth quarter earnings call. I'm Molly, the new Group CEO since the end of last year after leading the Veterinary Services segment for the past four years. To give you some background, during my four years as Head of Veterinary Services, the business developed from a Northern European purchasing organization into a global service platform with over 10,000 member clinics. I've personally experienced the company's ability to attract talent and entrepreneurs and take something relatively, relatively small with potential and build it into global scale and a market leader. I'm a firm believer in our strategy of organic and acquisition-driven growth, and we operate in an exciting and resilient industry going through change. I know the sector, the customers, the business and our organization well, and I'm confident about our industry and future.
We will now go through the full year and fourth quarter and will later give you deeper insights into the financials. Looking back at full year 2025, we delivered revenue growth of 13% and adjusted EBITDA growth of 11%. We saw broad-based growth across most of our businesses, not least in Specialty Pharma, Veterinary Services, and our MedTech dental businesses. We also put in focused efforts to address the headwinds within MedTech Orthopedics, in particular in the US.
In fall, we received a positive judgment in the US indemnification process, and all counterparts have now, as of year-end, paid us in full. The year also delivered a strong operational cash flow of €105.7 million, corresponding to a cash conversion of 101%.
Last but not least, we also completed the list change to Nasdaq Main Market, where we are now a large cap company.
Going deeper into Q4 and looking at the quarter, we delivered a solid finish to 2025 with 6% organic growth and 6% adjusted EBITDA growth, excluding currency effects. Adjusted EBITDA grew by 12% excluding currency effects. We saw continued momentum within our Specialty Pharma segment. We saw a strong finish with MedTech Dental while active measures were taken in the quarter. Within MedTech Orthopedics, efforts were ongoing, while Veterinary Services continued to perform at scale, reaching over 10,000 members.
And in the quarter, we increased our M&A activity with three acquisitions across three different segments and expanded our M&A pipeline.
The past few months ahead of 2026 included I-Vet. An important milestone for the Diagnostics segment was an acquisition signed just before Christmas to strengthen the companion animal offering within that segment. The quarter also delivered strong cash conversion.
Looking at Q4, we had 4% revenue growth to €109 million. Our organic revenue growth was 6%, driven by Specialty Pharma, Veterinary Services, and our MedTech dental business, with 3% contributions from acquisitions, and we saw a 4% negative impact from currency movements, in particular, movements in the US dollar. We improved our margin by 60 basis points versus Q4 2024, driven by bolt on acquisitions and delivered 6% adjusted EBITDA growth for the quarter.
And as I said before, excluding currency effects, Adjusted EBITDA grew. The growth was 12%. Looking at Specialty Pharma, we continue to see positive performance in the fourth quarter with 6% organic growth following an exceptionally strong Q4 2024, where we reported 22% organic growth, normalizing the positive effects from the national sales campaign in the US in the fourth quarter of 2020. The underlying organic growth was double-digit in the fourth quarter this year. All four therapeutic areas delivered growth in the quarter, with the strongest contribution from our dermatology portfolio. Overall, organic growth continues to be driven by our innovation, cross-selling activities, and veterinary education. Adjusted EBITDA grew 4%, or 7% when adjusted for currency effects, to €13.8 million, which is an all-time high quarter for us. The margin improved from 29.4% to 30%, driven by revenue growth and stronger gross margin for the full year. Specialty Pharma grew 6% to €182.4 million and adjusted EBITA by 10% to €53.9 million.
In January, our head of Specialty Pharma, Magnus, announced his departure after ten years in the company. I believe the business stands strong, and the recruitment process for a successor is ongoing, and we've secured a strong transition plan with Karl-Johan as interim head of Specialty Pharma. As interim head of MedTech since the end of July. I'm happy to see the accelerated momentum in our dental business in the quarter, as well as early operational improvements within our orthopedic business, although we still have work to be done and the market remains soft.
In total, we delivered 4% organic growth in the fourth quarter, supported by strong growth in our dental business and orthopedics in Europe and APAC. Within orthopedics, we have implemented a reorganization in the quarter with a focus on strengthening commercial performance. We built out our field sales organization in the US, and we reviewed and rationalized our product portfolio, where we had over 22,000 SKUs and have decided to discontinue over 4,000 overlapping SKUs.
We are still in a transition phase in US Orthopedics during early 2026. We continue to drive sequential sales improvements, but do not expect Orthopedics to deliver year-on-year growth until later in spring.
The recruitment for a permanent head of MedTech is ongoing and progressing well. The margin in the quarter of 24.6% is a 370 basis point improvement versus Q4 2024, mainly driven by the consolidation of the Bolton acquisition within dentistry in 2025. Adjusted EBITDA grew 23% in the quarter and 32% excluding currency effects. For the full year, MedTech grew revenues by 25% to €155.5 million. Where our acquisitions within dentistry contributed 30%, full year adjusted EBITDA grew 15% to€39.6 million. Veterinary services delivered another strong quarter with 10% organic growth.
In October, we completed the acquisition of a local service platform in Belgium with 300 member clinics and passed the 10,000 milestone when it comes to member clinics, closing the year with 10,900 member clinics. As previously communicated, we are accelerating our investments into new geographies and services in the quarter, taking the margin to 26.6% for the full year. Veterinary Services increased revenues by 11% to €64.3 million, and adjusted EBITDA grew 9% to €18.4 million. Michael Tunnell, who has been part of Veterinary Services since 2018, was appointed Head of Veterinary Services when I became CEO, and I'm pleased to see how the team has come together and continues to build momentum for the global Veterinary Services platform.
Our diagnostic business reported 5% organic growth in the quarter and a margin of 9.2%, reflecting our investments in new products and personnel to strengthen the companion animal offering. The growth was supported by bluetongue outbreaks in Europe and avian influenza globally. For the full year, Diagnostics grew by 9% to €22.9 million, while adjusted EBITDA declined 3% to €2.2 million. As I said initially, we welcomed five new businesses in 2025 that expanded our portfolio and geographic footprint.
We've seen improving M&A momentum towards the end of the year, with three out of these five acquisitions coming in the fourth quarter. We've built a stronger pipeline over the past months, and I'm optimistic about the M&A opportunities going into 2026. We continue to focus on successful, entrepreneurial-led businesses that can grow and reach their full potential faster as part of Immune. A good example of that is I-Vet that we signed in December.
I-Vet is one of the top three in companion animal diagnostics in Italy and forms an important addition to our diagnostic segment. I-Vet is a typical acquisition, a high-growth, successful, and entrepreneurial-led business where the entrepreneur, Daniela, is highly motivated and will continue to lead the business as part of Immune. Annual revenues of €5.6 million, with two thirds of their revenues coming from laboratory services (they have three labs in Italy), and the remaining third from sales of in-clinic diagnostic tests. I-Vet also has a well-known educational platform with over 100 courses annually, and offers residency programs in partnership with universities.
Looking at our sustainability as we now close 2025, we can see that we continue to make important progress within our ESG agenda. Our sustainability agenda is closely integrated into the core of the business and focuses on animal health, our people, and the planet. During 2025, we educated 65,000 veterinary professionals to improve animal health, and we launched 94 new products to advance veterinary medicine. Our Employee Net Promoter score reached 30, and we have exceptionally high scores from our teams in areas of inclusion, trust and autonomy. On the environmental side, we continue to reduce our emissions by a total of 25% since 2022. We also received external recognition for our work, with an improved rating at both MSCI to AA and Sustainalytics to low risk.
With that run through of the year and the quarter, I will now hand over to you.